The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

M Black, Dennis; R Reid, Ian; Boonen, Steven; Bucci-Rechtweg, Christina; A Cauley, Jane; Cosman, Felicia; R Cummings, Steven; F Hue, Trisha; Lippuner, Kurt; Lakatos, Peter; Chung Leung, Ping; Man, Zulema; Lou Maria Martinez, Ruvie; Tan, Monique; Ellen Ruzycky, Mary; Su, Guoqin; Eastell, Richard

doi:10.1002/jbmr.1494

Public

The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

Shared by NobleBlocks on Feb 1, 2012 • 12:00 AM UTC

Authors:

Dennis M Black

Ian R Reid

Steven Boonen

Abstract

Zoledronic acid 5 mg (ZOL) annually for 3 years reduces fracture risk in postmenopausal women with osteoporosis. To investigate long-term effects of ZOL on bone mineral density (BMD) and fracture risk, the Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly-Pivotal Fracture Trial ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!